Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03KAC
|
|||
| Former ID |
DCL000262
|
|||
| Drug Name |
XL147
|
|||
| Synonyms |
N-[3-(2,1,3-Benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; 956958-53-5; XL147 analogue; PI3K inhibitor X; XL 147; Pilaralisib analogue; N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide; CHEBI:71957; C21H16N6O2S2; N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide; Benzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-; 1033110-57-4; PubChem22457; XL-147 derivative 2; cc-43; AC1Q2LO8; AC1LZ6F0; SAR245408 + MSC1936369B
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Exelixis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H16N6O2S2
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4
|
|||
| InChI |
1S/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)
|
|||
| InChIKey |
MQMKRQLTIWPEDM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1033110-57-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
2292548, 7613915, 9162512, 25687318, 32753982, 47324138, 53012507, 85758375, 88887486, 99436990, 110757007, 117413884, 124757013, 125163817, 125655166, 126626058, 126658546, 126729189, 131480692, 134964436, 135698922, 136340109, 136367315, 137102005, 140639648, 143499694, 151981971, 152234899, 152258322, 152344014, 160647161, 160962901, 162011393, 162037447, 162202599, 163772970, 163907945, 164042763, 164077913, 164825243, 164836213, 166698477, 170503349, 174006505, 174531402, 177748775, 185967759, 215730822, 223388734, 223686141
|
|||
| ChEBI ID |
CHEBI:71957
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7963). | |||
| REF 2 | Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb;136(2):246-53. | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). | |||
| REF 4 | The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.Mol Cancer Ther.2015 Apr;14(4):931-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.